Tego Science’s cell therapy product, TPX-115, has shown more excellent efficacy than platelet-rich plasma (PRP) treatment, a local research team said Monday based on a trial using an animal model.The non-clinical thesis to that effect, written by a group of researchers led by Professor Oh Ju-han of
Hanmi Pharmaceutical said it has transferred rights for Luminate (ingredient: Risuteganib), an innovative new drug in ophthalmology, to AffaMed Therapeutic, a Chinese-based pharmaceutical company.Luminate is a new retinal disease drug developed by Allegro Ophthalmics, a U.S.-based R&D company specia
DongWha Pharm has obtained the approval for its new oral digestive medicine, Whaljjakjeong, once again.Industry watchers are paying attention to whether the digestive pill, which had failed to make its commercial debut over the past four years since it won the initial permission, will be able to cro
LegoChem Bioscience and ABL Bio said Monday that their global partner CStone Pharmaceuticals has received investigational new drug (IND) approval for CS5001, antibody-drug conjugate (ADC) anticancer drug candidate jointly developed by the two Korean companies.LegoChem Bio licensed out the developmen
Daewoong Pharmaceutical said that it has submitted a biologics license application (BLA) for its botulinum toxin (BTX) product Nabota treating forehead wrinkles to China’s National Medical Products Administration (NMPA).Daewoong completed the phase 3 clinical trial of Nabota in China in July under t
A day after Biogen's stock price jumped upon news that Samsung Group was in talks to acquire the Boston-based biotech, the Korean conglomerate group denied the media report as “not true.”The Korea Economic Daily, a vernacular financial paper, reported on Thursday that Samsung Group is reportedly neg
Daewoong Pharmaceutical said Thursday that its Fexuclue has won regulatory approval as a new drug for gastroesophageal reflux disease (GERD).The company said the Ministry of Food and Drug Safety authorized 40 milligrams of Fexuclue for erosive GERD. It plans to apply for setting the share of insuran
The Samsung Group is reportedly negotiating with Biogen to buy out the U.S. pharmaceutical company in a deal that may be worth up to $42 billion, according to a vernacular financial paper citing investment banking sources.On Wednesday, the Korea Economic Daily reported that if the deal is confirmed,
Yuhan Corp. has registered the patent of Esopid Tab. (esomeprazole magnesium trihydrate/calcium carbonate), a treatment for gastroesophageal reflux disease (GERD), to block the entry of latecomers and counter rivals in the proton pump inhibitor (PPI) plus antacid combination therapy market.Industry
Moderna, a biotech company developing messenger RNA (mRNA) therapeutics, has revealed a revised agreement to supply 20 million doses of its Covid-19 vaccines and updated booster candidates to Korea in 2022.Under the new accord, the company will provide 15 million doses for delivery in the third quar
Vivozon Pharmaceutical, which was punished for making drugs in unauthorized methods earlier this year, has been recently ordered to recall and discard medicines due to the same GMP violation.The Ministry of Food and Drug Safety said on Monday that it would urgently request a recall of two medicines
An increasing number of Korean pharmaceutical and biotech companies are collaborating with the Coalition for Epidemic Preparedness Innovations (CEPI) to tap the global vaccine market.CEPI is an international private organization established in 2017 to support vaccine development to fight infectious
CancerRop held an extraordinary general meeting of shareholders on Thursday and decided to change the company name, appoint new board directors, and change some of the articles of incorporation.During the extraordinary general meeting of shareholders, the company specializing in molecular diagnosis
SK bioscience said that it has expanded its collaboration and license agreement with Novavax concerning the latter's NVX-CoV2373, a recombinant nanoparticle protein-based Covid-19 vaccine.Under the expanded contract, SK bioscience will reserve additional manufacturing capacity to produce an antigen,
AstraZeneca’s booster dose of the Covid-19 vaccine and an antibody combination therapy Evusheld (tixagevimab/cilgavimab) effectively prevented infection with the Omicron variant, studies showed.The research team of University College Oxford, U.K., and Washington University School of Medicine, St. Lo
inno.N said the company has licensed out its gastroesophageal reflux disease (GERD) therapy, K-CAB, to Braintree Laboratories, a subsidiary of Sebela US, a U.S.-based pharmaceutical company.The total contract size is 640 billion won ($540 million), the largest single contract achieved by the company
Korean vaccine developers are racing to develop a vaccine against the Omicron variant, which is likely to be the dominant variant within a few months in the nation.Rep. Lee Kwang-jae and Shin Hyun-young of the Democratic Party held a meeting with officials from local vaccine developers on Wednesday
Amgen said its oral PDE4 inhibitor Otezla (ingredient: apremilast) obtained FDA’s approval for expanded indication to treat mild to moderate plaque psoriasis. With the latest nod, Otezla became the only oral systemic treatment that can be used for all stages of plaque psoriasis.Amgen acquired owners
LG Chem said it completed recruiting participants for a phase 1 clinical trial of non-alcoholic steatohepatitis (NASH) treatment in the U.S.According to clinicaltrials.gov, LG Chem updated the status of the phase 1 trial of TT-01025 on Nov. 24.The updates displayed that the status of participant enr
In January every year, all eyes of global biopharmaceutical companies are on the J.P. Morgan Health Conference, the largest healthcare conference in the world that draws institutional investors’ attention worldwide.For the same reason, many Korean drugmakers will participate in the 2022 conference d